GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

Roche has pledged to build a giant weight-loss drug factory in the US. The plans form part of a $50bn (£37bn) pledge aimed at ...

This FTSE 100 firm's smaller than rivals but could benefit from its big US manufacturing footprint and competitive market ...